Brian Wainger News Today : Breaking News, Live Updates & Top Stories | Vimarsana

It's possible it could oversee any litigation surrounding the OceanGate submersible, too.

(BUSINESS WIRE)--QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports.

Updated Dec 14, 2020 | 11:13 IST A study suggests that the antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with ALS. Consuming the antiepileptic drug in ALS can reduce motor neuron excitability | Photo Credit: Pixabay  Washington: A new study suggests that the antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS). T...

Consuming antiepileptic drug in ALS can reduce motor neuron excitability ANI | Updated: Dec 13, 2020 18:19 IST Washington [US], December 13 (ANI): A new study suggests that the drug-ezogabine">drug">antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS). The study was conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition to providing a clearer understanding...

The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital.